SCHEMBL4663907

SCHEMBL4663907

Cc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc5c(ccn5CC5CCN(C)CC5)c4)ncn3)cc2)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 6/20 0.34
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
ABL1 P00519 5/20 0.33
BCR P11274 5/20 0.33
BACE1 P56817 2/20 0.33
CDK1 P06493 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665806 0.94 MEN1 (0.36) KDM1AMEN1USP2ALDH1A1TP53
SCHEMBL4663796 0.92 ABL1 (0.36) KDM1AMEN1USP2ALDH1A1TP53
SCHEMBL4665685 0.90 HTR7 (0.35) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4666040 0.89 MEN1 (0.36) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4665687 0.89 MEN1 (0.39) KDM1AMEN1USP2ALDH1A1TP53
SCHEMBL4664038 0.88 EGFR (0.35) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4664241 0.88 AXL (0.36) KDM1AMEN1USP2ALDH1A1TP53
SCHEMBL4667361 0.88 MEN1 (0.32) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4663827 0.87 ABL1 (0.36) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4667453 0.87 ABL1 (0.34) KDM1AMEN1USP2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 KDM1A 727/4885MEN1 3892/4885USP2 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.